[Effect of propranolol therapy on the secretion of insulin, glucagon, gastrin and pancreatic polypeptide in patients with essential hypertension].
A group of 20 patients with primary hypertension (NT) were studied for the influence of six-week propranolol therapy on the secretion of immunoreactive insulin (IR-I), gastrin glucagon (IR-G) and pancreatic polypeptide (IR-PP) induced by a high-fat test meal. The results of the examination before the therapy were compared with examination of 10 healthy persons. Before the therapy, the patients with NT revealed a decreased reactivity of IR-PP to the food stimulus. After propranolol therapy, the authors found a significant change of glucagonemia profile and pancreatic polypeptide concentration induced by a test meal. The results of the examinations made suggest a direct or indirect participation of beta-adrenergic endings in the regulation of glucagon and pancreatic polypeptide secretion in patients with primary hypertension.
Zukowska-Szczechowska
E
E
Kokot
F
F
D000293:Adolescent; D000328:Adult; D005260:Female; D005755:Gastrins / Q000378:metabolism*; D005934:Glucagon / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D008875:Middle Aged; D010187:Pancreatic Hormones / Q000378:metabolism*; D010191:Pancreatic Polypeptide / Q000378:metabolism; D011433:Propranolol / Q000627:therapeutic use*
D005755:Gastrins; D007328:Insulin; D010187:Pancreatic Hormones; D010191:Pancreatic Polypeptide; D005934:Glucagon; D011433:Propranolol
Wpływ leczenia propranololem na sekrecje insuliny, glukagonu, gastryny i polipeptydu trzustkowego u chorych na samoistne nadciśnienie tetnicze.